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Abstract 
Aberrant activation of the nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin 
domain containing 3 (NLRP3) inflammasome drives the development of many complex inflammatory diseases, 
such as obesity, Alzheimer’s disease, and atherosclerosis. However, no medications specifically targeting the 
NLRP3 inflammasome have become clinically available. Therefore, we aim to identify new inhibitors of the 
NLRP3 inflammasome in this study. 
Methods: Vesicle-like nanoparticles (VLNs) were extracted from garlic chives and other Allium vegetables and 
their effects on the NLRP3 inflammasome were evaluated in primary macrophages. After garlic chive-derived 
VLNs (GC-VLNs) were found to exhibit potent anti-NLRP3 inflammasome activity in cell culture, such function 
was further assessed in a murine acute liver injury disease model, as well as in diet-induced obesity. Finally, 
GC-VLNs were subjected to omics analysis to identify the active components with anti-NLRP3 inflammasome 
function. 
Results: GC-VLNs are membrane-enclosed nanoparticles containing lipids, proteins, and RNAs. They 
dose-dependently inhibit pathways downstream of NLRP3 inflammasome activation, including caspase-1 
autocleavage, cytokine release, and pyroptotic cell death in primary macrophages. The inhibitory effects of 
GC-VLNs on the NLRP3 inflammasome are specific, considering their marginal impact on activation of other 
inflammasomes. Local administration of GC-VLNs in mice alleviates NLRP3 inflammasome- 
mediated inflammation in chemical-induced acute liver injury. When administered orally or intravenously, 
GC-VLNs accumulate in specific tissues and suppress activation of the NLRP3 inflammasome and chronic 
inflammation in diet-induced obese mice. The phospholipid 1,2-dilinoleoyl-sn-glycero-3-phosphocholine 
(DLPC) in GC-VLNs has been identified to inhibit NLRP3 inflammasome activation. 
Conclusions: Identification of GC-VLNs and their active component DLPC as potent inflammasome 
inhibitors provides new therapeutic candidates in the treatment of NLRP3 inflammasome-driven diseases. 
Key words: Nanoparticles, vesicles, garlic chive, NLRP3 inflammasome, obesity 
Introduction 
The NLRP3 inflammasome protein complex is 
formed by NLRP3, apoptotic speck protein containing 
a caspase recruitment domain (ASC) and caspase-1 
(Casp1) [1,2]. As a vital player in the innate immune 
system, NLRP3 inflammasome’s activation is tightly 
regulated through a two-step process − it must first be 
primed and then be assembled [3,4]. Priming signals, 









factor alpha (TNFα), upregulate transcription of the 
Nlrp3 and Il1b genes through activation of nuclear 
factor-κB (NF-κB) signaling and induce post- 
translational modifications of NLRP3 protein. A 
variety of stimuli from pathogens, hosts, or the 
environment, such as nigericin, adenosine 
triphosphate (ATP), alum, serve as activating signals 
to trigger the assembly and activation of the NLRP3 
inflammasome, leading to autocleavage of Casp1. 
Casp1 cleaves itself to generate Casp1 p10 and p20, 
which in turn cleave 1) gasdermin D to induce 
pyroptotic cell death and 2) pro-interleukin (IL)-1β 
and pro-IL-18 to release mature cytokines IL-1β and 
IL-18. Genetic evidence indicates that both cytokine 
release and pyroptosis are essential contributors to the 
NLRP3 inflammasome-mediated inflammatory 
process [5]. Inappropriate activation of the NLRP3 
inflammasome has been implicated in many diseases, 
such as obesity [6], cryopyrin-associated 
autoinflammatory syndrome [7], Alzheimer’s disease 
[8], atherosclerosis [9], and gout [10]. Therefore, the 
NLRP3 inflammasome has been considered to be a 
highly desirable drug target, but therapeutics 
specifically targeting this protein complex has not 
become available in clinical practice. 
In obesity, the increased levels of circulating LPS 
from gut microbiota [11,12] and accumulated 
metabolic stress molecules (such as free fatty acids 
[FFAs] and cholesterol crystals) [2-4] act as the 
priming and activating signals, respectively, and lead 
to assembly and activation of the NLRP3 
inflammasome. Reduced expression of the NLRP3 
gene in adipose tissue is correlated with decreased 
inflammation and improved insulin sensitivity in 
obese type 2 diabetic patients [6]. Genetic deletion of 
the Nlrp3, Pycard (Asc), or Casp1 genes has been shown 
to improve glucose homeostasis, accompanied by 
decreased inflammatory cytokines in the serum and 
reduced expression of inflammatory genes in adipose 
tissues in diet-induced obese mice [6,13,14]. 
Fulminant hepatic failure is a rare acute hepatic 
disorder associated with high mortality [15]. 
Administering D-galactosamine (GalN) and LPS in 
mice induces acute inflammation and liver injury, 
simulating many clinical features of fulminant hepatic 
failure [16]. The chemical inhibitor of the NLRP3 
inflammasome, MCC950, alleviates inflammation and 
liver damage in GalN/LPS-challenged mice [17], 
suggesting critical involvement of the NLRP3 
inflammasome in this disease model. 
Dietary vesicle-like nanoparticles (VLNs) have 
been recently identified in many commonly 
consumed foods, including bovine milk, broccoli, 
ginger, apple, and honey [18-22]. These dietary VLNs 
are membrane-enclosed nanoparticles (50-300 nm in 
diameter) containing proteins, lipids, and RNAs. 
Growing evidence indicates that dietary VLNs are 
stable, bioavailable, and bioactive in consumers. The 
membrane of a dietary VLN encloses the 
biomolecules inside the nanoparticle, thus conferring 
stability and resistance to solutions in the stomach 
and intestines and protecting the biomolecules from 
degradation [23]. As a result, dietary VLNs are able to 
reach target tissues where they exert their bioactivity. 
For example, it has been found that orally 
administered ginger VLNs accumulate in the liver, 
induce expression in the liver of detoxifying/ 
antioxidant genes, including Hmox1, Nqo1, Gclm, and 
Gclc, and ameliorate liver damage caused by alcohol 
consumption in mice [24]. Grape-derived VLNs are 
taken up by intestinal stem cells and promote their 
proliferation through regulation of the Wnt/β-catenin 
signaling pathway [25]. The bioavailability, stability, 
and bioactivity of these dietary VLNs confer upon 
them high therapeutic potential. Therefore, we sought 
to screen dietary VLNs for anti-NLRP3 inflammasome 
activities. 
Results 
Characterization of VLNs from garlic chives 
Many species in the genus Allium, such as garlic, 
leek, onion, and scallion, are commonly consumed 
throughout the world. Many of them have 
anti-inflammatory properties [26]. Therefore, in this 
study, we selected six vegetables from the Allium 
genus for VLN extraction and assessed the effects of 
their VLNs on the NLRP3 inflammasome. Bulbs of 
garlic (A. sativum) and purple or white onion (A. cepa) 
and leaves of leek (A. ampeloprasum), scallion (A. 
fistulosum), and garlic chive (A. tuberosum) were 
minced and subjected to VLN extraction using the 
protocol established in our laboratory [19,27]. VLNs 
were obtained from all Allium vegetables. 
Nanoparticle tracking analysis (NTA) showed that 
sizes of Allium-derived VLNs ranged from 113 nm to 
153 nm in diameter (Figure S1A). The yields of 
Allium-derived VLNs varied from 1.5×1011 g-1 to 
8.9×1011 g-1 (Figure S1B). To evaluate the effects of 
Allium-derived VLNs on NLRP3 inflammasome 
activity, these nanoparticles were incubated with 
murine bone marrow-derived macrophages 
(BMDMs), followed by NLRP3 inflammasome 
activation using LPS and ATP. Antibodies against 
macrophage surface markers F4/80 [28] and CD11b 
[29] were used to validate the macrophage identity of 
BMDMs. Over 96% of BMDMs were F4/80 and 
CD11b double positive (Figure S1C), suggesting that 
the majority of BMDMs were indeed macrophages. 
Most Allium-derived VLNs had marginal or mild 





inhibitory effects on the level of the Casp1 
autocleavage product Casp1 p10 in cell lysates upon 
activation of the NLRP3 inflammasome, but GC- 
VLNs strongly inhibited Casp1 autocleavage (Figure 
S1D). Therefore, GC-VLNs were chosen for further 
studies. 
The vesicle-like features of GC-VLNs were 
assessed in detail. Scanning electron microscopy 
(SEM) showed that GC-VLNs were well-dispersed 
individual ball-like nanoparticles (Figure 1A), and 
ultrastructure transmission electron microscopy 
(TEM) demonstrated that GC-VLNs were enclosed by 
a membrane structure (Figure 1B). Detergent 
treatment is a simple way to distinguish between 
protein aggregates and membrane-enclosed particles, 
because protein aggregates are much more resistant to 
detergent-based lysis than membrane-bound particles 
[30]. The non-ionic detergent Triton X-100, which 
disrupts lipid-lipid interaction and lipid-protein 
interaction [30], was found to lyse GC-VLNs and 
therefore reduce GC-VLN numbers in a 
dose-dependent manner (Figure 1C), further 
confirming the membrane-bound nature of GC-VLNs. 
Biomolecule analysis revealed that these 
nanoparticles contained small-sized RNAs, proteins, 
and lipids (Figure 1D-F). 
The proteins in GC-VLNs were subjected to 
proteomics analysis using the reference proteome 
database viridiplantae, because the proteome of garlic 
chive was unavailable. A variety of proteins were 
identified in GC-VLNs (Table S1). A series of plasma 
membrane proteins, such as plasma membrane 
ATPase, ABC transporter G family member, 
pleiotropic drug resistance protein, and 
hypersensitive-induced response protein, were found 
in GC-VLNs. Clathrin heavy chain and light chain 
and Ras-related protein, cytosolic proteins that are 
known to associate with plasma membrane [31,32], 
were identified in GC-VLNs. The presence of plasma 
membrane proteins and cytosolic proteins that 
interacted with the plasma membrane in GC-VLNs 
supported their vesicle-like properties. 
GC-VLNs suppressed NLRP3 inflammasome 
activation 
In obesity, increased levels of LPS and FFA often 
serve as priming and activating signals, respectively, 
to activate the NLRP3 inflammasome [33]. Therefore, 
to mimic obesity condition in vitro, we first pre-treated 
BMDMs with GC-VLNs, followed by LPS priming 
and FFA treatment to activate the NLRP3 
inflammasome. Remarkably, GC-VLNs suppressed all 
the downstream events of NLRP3 inflammasome 
activation in a dose-dependent manner, including 
Casp1 autocleavage (Figure 2A), IL-1β secretion 
(Figure 2B), IL-18 secretion (Figure 2C), and 
pyroptosis (Figure 2D). We were not able to detect the 
Casp1 autocleavage product Casp1 p10 and its 
cleaved mature IL-1β in the culture media using 
immunoblot analysis, possibly because of relative 
weak activation of the NLRP3 inflammasome by FFA. 
The levels of Casp1 p10 in cell lysates are generally 
consistent with its levels in culture media [34-36]. 
Therefore we conducted immunoblot analysis of 
Casp1 p10 using cell lysates to monitor the Casp1 
autocleavage status. Activation of NF-κB signaling via 
 
 
Figure 1. Characterization of GC-VLNs. (A) Representative SEM images of GC-VLNs. (B) Ultrastructure TEM images of GC-VLNs. (C) Effects of Triton X-100 treatment 
on nanoparticle numbers of GC-VLNs. Triton X-100 (TX) at different concentrations was used to lyse GC-VLNs, followed by measurement of particle numbers. Results were 
expressed as mean±SEM from three independent experiments. * (p < 0.05) and ** (p < 0.01) compared with the sample without Triton X-100 treatment (black bar). (D) Agarose 
gel of RNAs extracted from GC-VLNs. 2.5% agarose gel was used. RNA ladder: 50-1000 nucleotides (nt). (E) Coomassie blue staining of protein gel of GC-VLN proteins. 4-12% 
NuPAGE Bis-Tris protein gel was used. Protein ladder: 10-250 kDa. (F) CuSO4/phosphoric acid staining of GC-VLN lipids on a thin layer chromatography (TLC) silica gel plate. 
10% CuSO4 in 8% phosphoric acid was used to visualize the lipid bands. 





LPS priming leads to release of two potent cytokines 
IL-6 and TNFα [37]. Interestingly, GC-VLNs also 
suppressed the release of both IL-6 and TNFα (Figure 
S2A-B). In peritoneal macrophages, GC-VLNs also 
suppressed Casp1 autocleavage when the NLRP3 
inflammasome was activated using LPS and FFA 
(Figure 2E). The inhibitory effects of GC-VLNs on the 
NLRP3 inflammasome were specific because 
GC-VLNs did not inhibit Casp1 autocleavage 
mediated by the Absent in Melanoma 2 (AIM2) 
inflammasome (Figure 2F). AIM2 senses cytosolic 
DNAs during bacterial or viral invasion, recruits ASC 
and Casp1 to form the AIM2 inflammasome, and 
leads to Casp1 autocleavage and activation [1,2]. 
ATP is a commonly used stimulus to activate the 
NLRP3 inflammasome [38]. When the NLRP3 
inflammasome was activated by ATP in LPS-primed 
BMDMs, GC-VLNs dose-dependently decreased the 
level of Casp1 p10 in the cell lysates and culture 
media (Figure 2G). IL-1β release was also decreased 
by GC-VLN treatment, as indicated by IL-1β 
immunoblot analysis of the media (Figure 2G) and 
IL-1β ELISA analysis (Figure S3A). Secretion of IL-18 
and pyroptotic cell death were consistently alleviated 
by GC-VLNs (Figure S3B-C). GC-VLNs also blunted 
Casp1 autocleavage when the NLRP3 inflammasome 
was activated by ATP in LPS-primed peritoneal 
macrophages (Figure S3D). A time-course experiment 
demonstrated that incubation for at least 6 h was 
needed for GC-VLNs to inhibit NLRP3 
inflammasome-mediated Casp1 autocleavage (Figure 
S3E). In addition, GC-VLNs inhibited NLRP3 
inflammasome-mediated Casp1 autocleavage when it 
was activated by other stimuli, such as nigericin or 
alum (Figure 2H). 
The cellular events targeted by GC-VLNs during 
NLRP3 inflammasome activation were further 
investigated. GC-VLNs had marginal effects on the 
levels of either inflammasome subunits (NLRP3, 
Casp1, and ASC), pro-IL-1β, or the critical 
inflammasome modulator never in mitosis gene a 
(NIMA)-related kinase 7 (Nek7) [35] (Figure S4A). 
When the sensor NLRP3 is activated, it forms 
oligomers, recruits the adaptor ASC, and induces ASC 
oligomerization. The oligomerized ASC further 
recruits the effector Casp1 to form an oligomerized 
protein complex with high molecular mass [39]. The 
ASC oligomerization assay showed that GC-VLNs 
suppressed ASC oligomerization (Figure S4B). The 
NLRP3 inflammasome complex with high molecular 
mass can be detected as a single speck in each 
macrophage cell using ASC immunofluorescence 
staining [35]. GC-VLN treatment reduced the speck 
formation in BMDMs (Figure S4C-D). Therefore, 
GC-VLNs seemed to impede assembly and formation 
of the NLRP3 inflammasome complex. 
 
 
Figure 2. GC-VLNs specifically inhibited NLRP3 inflammasome activation. (A-D) BMDMs were preincubated with GC-VLNs for 16 h, primed with LPS for 3 h, and 
stimulated with FFA sodium palmitate for 12 h to activate the NLRP3 inflammasome. Cells were lysed for immunoblot analysis of Casp1 p10 (A), and the cell-free media were 
subjected to enzyme-linked immunosorbent assay (ELISA) analysis to measure the release of IL-1β (B) and IL-18 (C). Pyroptotic cell death was assessed by measuring the level 
of lactate dehydrogenase (LDH) released in the culture media (D). (E) Immunoblot analysis of Casp1 p10 in lysates of peritoneal macrophages preincubated with GC-VLNs for 
16 h, followed by NLRP3 inflammasome activation using LPS and FFA. (F) Immunoblot analysis of Casp1 p10 in cell lysates of BMDMs preincubated with GC-VLNs for 16 h, 
followed by AIM2 inflammasome activation. (G) Immunoblot analysis of Casp1 and IL-1β in cell lysates and culture media of BMDMs preincubated with GC-VLNs for 16 h, primed 
with LPS for 3 h, and stimulated with ATP for 30 min to activate the NLRP3 inflammasome. (H) Immunoblot analysis of Casp1 p10 in lysates of LPS-primed BMDMs, in which the 
NLRP3 inflammasome was activated by nigericin (Ni) or alum. 9×1010 mL-1 of GC-VLNs were used to pretreat the cells for 16 h. Results were expressed as mean±SEM from three 
independent experiments. * (p < 0.05) and ** (p < 0.01) compared with LPS+FFA group (black bar). Tubulin was included to show equivalent loading in immunoblot analysis. 
LPS-treated macrophages were used as a negative control for inflammasome activation. 






Figure 3. GC-VLNs alleviated inflammation in chemical-induced acute liver injury in mice. 8-week-old male C57BL/6J mice were intraperitoneally injected with the 
solvent phosphate-buffered saline (PBS) or GC-VLNs in PBS at 1×1010 g-1. 48 h later, acute liver injury was induced by intraperitoneal injection of GalN/LPS mixture. The mice 
were sacrificed 6 h after GalN/LPS injection. N = 4/group. (A) Representative images of liver sections with hematoxylin and eosin (H&E) staining. (B) Levels of AST and ALT in 
serum. (C) Levels of IL-1β in serum. (D) Levels of IL-18 in serum. (E) Relative mRNA levels of Nlrp3, Pycard, Casp1, and Il1b genes in the livers. The housekeeping gene 
hypoxanthine guanine phosphoribosyl transferase (Hprt) was used to normalize mRNA levels. (F) Immunoblot analysis of liver lysates. Data were presented as mean±SEM. * (p 
< 0.05) and ** (p < 0.01) compared with the control group (bar with white squares). 
 
GC-VLNs were labeled with a lipophilic dye 
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine 
perchlorate (DiI) and incubated with BMDMs. 
GC-VLNs were taken up by BMDMs in a 
dose-dependent manner (Figure S5A). In the 
time-course experiment, DiI-labeled GC-VLNs were 
detected in BMDMs after 3 h incubation and 
accumulated in cells over the time (Figure S5B). 
Proteins inside GC-VLNs were labeled with Exoglow 
protein dye, and these protein-labeled GC-VLNs 
accumulated dose-dependently in BMDMs (Figure 
S5C). When RNAs in GC-VLNs were labeled with 
Exoglow RNA dye, they were also readily detected in 
primary macrophages (Figure S5D). Together, these 
uptake experiments suggested that intact GC-VLNs 
and their contents (proteins and RNAs) were taken up 
by BMDMs. 
GC-VLNs reduced inflammation during acute 
liver injury 
Administration of GalN and LPS through 
intraperitoneal injection triggers acute liver injury and 
inflammation in mice [16]. MCC950, a specific 
chemical inhibitor of the NLRP3 inflammasome, 
suppresses inflammation and liver damage in this 
disease model [17]. We confirmed the critical 
involvement of the NLRP3 inflammasome in this 
disease model using a mouse strain without 
expression of the NLRP3 protein (Figure S6A). A 
mixture of GalN and LPS was injected in Nlrp3-/- mice 
and their wildtype (wt) littermates to induce acute 
liver injury. The mice were sacrificed after 6 h. The 
level of serum IL-1β in the Nlrp3-/- mice was much 
lower compared to their wt littermates after 
GalN/LPS challenge (Figure S6B), suggesting that 
acute inflammation in this disease model was largely 
dependent on the NLRP3 inflammasome. Therefore, 
this disease model was used to assess the anti-NLRP3 
inflammasome function of GC-VLNs in vivo in our 
initial proof-of-concept study. 
GC-VLNs were intraperitoneally injected into 
C57BL/6J mice. The therapeutic agent delivered 
through intraperitoneal injection would be primarily 
absorbed into the mesenteric vessels, drain directly 
into the portal vein, and pass through the liver [40]. 
Therefore, this local injection route was chosen to 
efficiently deliver GC-VLNs to the liver. Considering 
the absorption process of GC-VLNs, the minimum 6 h 
of treatment needed to observe the anti- 
inflammasome function of GC-VLNs in vitro, as well 
as our preliminary time-course in vivo test, we 
decided to wait for 48 h after GC-VLN administration 
to inject a mixture of GalN and LPS into mice to 
induce acute liver injury. GC-VLNs remarkably 
alleviated severe liver bleeding and cellular damage 
to hepatocytes caused by the GalN/LPS challenge 
(Figure 3A). The levels of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) in 





circulation are often used as indicators of liver injury 
[41]. GC-VLNs significantly lowered the circulation 
levels of ALT and AST induced by GalN/LPS (Figure 
3B). The levels of circulating IL-1β and IL-18, two 
downstream cytokines of NLRP3 inflammasome 
activation, were suppressed by GC-VLNs (Figure 
3C-D). In the livers, GC-VLNs reduced both mRNA 
and protein levels of the Nlrp3, Casp1, and Il1b genes 
(Figure 3E-F). GC-VLNs had no impact on the protein 
levels of NLRP3, Casp1, and pro-IL-1β in BMDMs 
(Figure S4A). The exact reasons for the differential 
effects of GC-VLNs in vitro and in vivo were not clear. 
It has been reported that mature IL-1β is responsible 
for recruiting macrophages [42]. Therefore, it is 
plausible that GC-VLNs suppressed the NLRP3 
inflammasome and thus led to diminished mature 
IL-1β, which in turn reduced macrophage infiltration 
and detection of inflammatory gene expression in 
liver tissue. Considering the inhibitory effects of 
GC-VLNs on IL-6 and TNFα in vitro, the levels of 
these cytokines in serum during acute liver injury 
were measured. Surprisingly, the levels of IL-6 and 
TNFα in circulation were not significantly affected by 
GC-VLNs (Figure S6C), but the transcription of Il6 
and Tnf genes was decreased by GC-VLN treatment 
(Figure S6D). Together, GC-VLNs reduced acute 
inflammatory responses and alleviated liver injury in 
GalN/LPS-challenged mice. The potent anti- 
inflammatory activities of GC-VLNs in acute liver 
inflammation prompted us to further investigate their 
therapeutic potential in chronic inflammation in 
obesity. 
GC-VLNs were distributed in specific tissues in 
mice 
The bioavailability of GC-VLNs in vivo was 
evaluated using fluorescence-labeled GC-VLNs. An 
ExoGlow-Vivo EV labeling kit was used to covalently 
link fluorescence dye to proteins on the membranes of 
GC-VLNs, which excluded the possibility of dye 
dissociation often reported for the lipophilic 
fluorescence dyes [24]. Systemic delivery of 
therapeutic agents is often achieved through 
parenteral (outside the digestive tract) and enteral 
(through digestive tract) administration [40]. 
Intravenous injection is a typical parenteral 
administration that leads to higher bioavailability, 
compared to enteral approaches, because it bypasses 
absorptive processes and hepatic metabolism of the 
agent. However, enteral approaches (typically oral 
administration) are less invasive and patient friendly. 
Therefore, we chose both intravenous and oral 
administration to assess the biodistribution of 
GC-VLNs. When GC-VLNs with fluorescence 
intensity (FI) of 3,500 g-1 were injected intravenously 
in lean healthy mice, the fluorescence signals of the 
GC-VLNs were detected in the liver, spleen, kidney, 
lung, brown adipose tissue (BAT), epididymal white 
adipose tissue (eWAT), and heart; however, 
intravenous injection of a free dye control with the 
same 3,500 FI g-1 led to no fluorescence signals in any 
of the examined tissues (Figure S7A-C). When 3,500 FI 
g-1 of GC-VLNs were given intravenously to 
diet-induced obese C57BL/6J mice, the labeled 
GC-VLNs accumulated in liver, spleen, kidney, lung, 
eWAT, heart, bone, and gastrointestinal (GI) tract 
(Figure 4A-B). It is interesting to note that the 
distribution patterns of GC-VLNs in lean and obese 
mice largely overlapped, with only a slight difference. 
For oral administration, we found that 60,000 FI 
g-1 (approximately 0.6×1010 nanoparticles g-1) of 
GC-VLNs were needed to detect fluorescence signals 
in the GI tract and kidney in lean mice (Figure S8A-C). 
Oral administration of free dye with the same 
fluorescence intensity led to detection of fluorescence 
signals in the GI tract. We reasoned that possible free 
dye contamination in 60,000 FI g-1 of GC-VLNs should 
be much lower than 60,000 FI g-1. In our labeling 
procedure, GC-VLNs were washed with PBS twice 
after labeling. The fluorescence intensity of free dye 
from the first wash was approximately 3,600/0.6×1010 
nanoparticles and the fluorescence intensity of free 
dye from the second wash was around 1,200/0.6×1010 
nanoparticles. Therefore, we decided to use free dye 
control at 7,000 FI g-1, which should be much higher 
than any possible contamination from free dye in the 
final labeled GC-VLNs. Oral administration of this 
free dye control did not lead to detection of significant 
fluorescence signal in any tissues (Figure S8A-C). 
When 60,000 FI g-1 of GC-VLNs were orally 
administered to diet-induced obese C57BL/6J mice, 
GC-VLNs were found in the GI tract, kidney, and 
eWAT (Figure 4A and C). The distribution patterns of 
orally administered GC-VLNs in lean and obese mice 
were also similar, but GC-VLNs accumulated 
significantly in eWAT in obese mice. 
GC-VLNs improved metabolic health and 
reduced inflammation in obesity 
To assess the effects of GC-VLNs on NLRP3 
inflammasome-mediated chronic inflammation in 
obesity, we fed C57BL/6J mice with a high-fat diet 
(HFD) for 15 weeks to induce obesity and 
obesity-associated chronic inflammation. When the 
HFD feeding was started, the mice were randomly 
separated into three groups: mice in the control group 
received PBS weekly; mice in VLN-IV group were 
administered with GC-VLNs weekly through 
intravenous injection (IV); and mice in VLN-OG 
group were given GC-VLNs weekly through oral 





gavage (OG). GC-VLNs had no significant effects on 
the body weight of mice during the entire experiment 
(Figure 5A). After 11 weeks of treatment, the mice 
were subjected to metabolic cage analysis. OG- or 
IV-administered GC-VLNs had marginal impact on 
food intake, water intake, and general activity (Figure 
5B), indicating that GC-VLNs did not cause any 
detrimental side effects in mice after 11 weeks of 
administration. After 13 weeks, mice were subjected 
to a glucose tolerance test. The mice treated with 
either IV- or OG-administered GC-VLNs cleared 
blood glucose more efficiently compared to the 
control group (Figure 5C-D), indicating improved 
glucose homeostasis in GC-VLN-treated mice. Upon 
sacrifice, the level of IL-6 in serum was found to be 
significantly lower in the VLN-IV group, and the level 
of serum IL-18 tended to be lower in both VLN-IV and 
VLG-OG mice, compared to the control mice, but the 
difference did not reach statistical significance (Figure 
5E). Levels of IL-1β and TNFα in the serum were 
undetectable in all the mice. 
Obesity-associated inflammation and NLRP3 
inflammasome activation initially arise in WAT 
[43,44]. Therefore, we mainly focused on the eWAT of 
these mice. Interestingly, the percentage of eWAT in 
the VLN-IV group was similar to that in the control 
group, but the percentage of eWAT in the VLN-OG 
group was higher than in the control group (Figure 
6A). In hematoxylin and eosin (H&E)-stained eWAT 
slides, crown-like structures (CLSs) were observed in 
the eWAT in diet-induced obese mice (Figure 6B, left 
panel). The CLSs, in which macrophages accumulate 
around dying or dead adipocytes, are a histologic 
hallmark indicating the proinflammatory state of 
eWAT [45,46]. GC-VLN treatment, especially in the 
VLN-OG mice, reduced the numbers of CLSs (Figure 
6B, middle and right panels). The stromal vascular 
fraction (SVF) of eWAT, which contains immune cells 
such as adipose tissue macrophages, adipose-derived 
stem cells, fibroblasts, and endothelial cells [47,48], 
 
 
Figure 4. Distribution of GC-VLNs covalently linked to a fluorescence dye in diet-induced obese mice. GC-VLNs were covalently labeled with a fluorescence dye 
in near infrared ranges. The labeled GC-VLNs were intravenously administered at 3,500 FI g-1 or orally given at 60,000 FI g-1 to male C57BL/6J mice, which were fed with a HFD 
for 15 weeks. 6 h later, the mice were sacrificed to collect tissues to measure the fluorescence signals in each type of tissue. N = 3/group. (A) Representative images of mouse 
tissues under Licor Odyssey Clx image system. (B) Fluorescence signal intensity of mouse tissues collected from control mice received with the solvent PBS and mice 
intravenously injected with GC-VLNs in PBS (VLN-IV). (C) Fluorescence signals of mouse tissues collected from control mice and mice orally administered with GC-VLNs 
(VLN-OG). Data were presented as mean±SEM. * (p < 0.05) and ** (p < 0.01) compared with the control PBS group (bar with white squares). 





was extracted, stained with antibodies against F4/80 
(surface marker of macrophages) [28], and subjected 
to flow cytometry analysis. Orally administered 
GC-VLNs remarkably reduced macrophage 
infiltration (Figure 6C-D). Both flow cytometry and 
histological analysis suggested that GC-VLNs 
reduced immune cell infiltration in eWAT in 
diet-induced obese mice. 
 
 
Figure 5. GC-VLNs improved metabolic health in diet-induced obese mice. 8-week-old male C57BL/6J mice were fed with a HFD, and GC-VLNs were given through 
oral gavage (VLN-OG) or intravenous injection (VLN-IV) at the dose of 1×1010 g-1 weekly when the HFD feeding started. N = 7-8 for each condition. (A) Body weight gain of the 
mice between 8 and 22 weeks of age. (B) Food intake, water intake, and movement counts. After 11-week treatment, the mice were individually kept in metabolic cages for 48 
h. The data from the final 24 h were used for the calculation. (C) Intraperitoneal glucose tolerance test (ipGTT). After 13-week treatment, the mice were intraperitoneally 
injected with 1 g kg-1 of glucose after 6 h of fasting. The blood glucose levels were monitored at the indicated intervals in the next 150 min. (D) Incremental area under the curve 
(AUC) for the ipGTT data in (C). (E) Levels of IL-6 and IL-18 in mouse plasma. Data were presented as mean±SEM. * (p < 0.05) and ** (p < 0.01) compared with the control PBS 
group (bar with white squares). 
 
Figure 6. GC-VLNs reduced immune cell infiltration in eWAT of diet-induced obese mice. The mice described in Figure 5 were sacrificed after 15-week treatment. 
eWAT was taken from each mouse and subjected to different analyses. (A) Weight percentage of eWAT/body weight. (B) Representative images of H&E-stained sections of 
eWAT. Yellow arrows indicate CLSs in eWAT. (C) Representative images of eWAT SVF stained with an anti-F4/80-APC antibody. SVF was extracted from eWAT, stained with 
the antibody which recognized macrophage surface marker F4/80, and subjected to flow cytometry analysis. To obtain enough cells, eWAT from 2 mice in each group were 
combined to extract SVF. (D) Quantification of adipose tissue macrophages (ATMs) using the data obtained in (C). Data were presented as mean±SEM. * (p < 0.05) and ** (p < 
0.01) compared with the control group (bar with white squares). 






Figure 7. GC-VLNs reduced inflammation in eWAT of diet-induced obese mice. The mice described in Figure 5 were sacrificed after 15-week treatment. One piece 
of eWAT was ex vivo cultured, primed with LPS for 3 h, and stimulated with FFA sodium palmitate for 12 h. (A) Levels of IL-1β, IL-18, IL-6, and TNFα in the culture media. The 
cytokine levels were normalized to the protein amount in each cultured eWAT. (B-C) Relative mRNA levels of inflammatory genes in eWAT, which were snap frozen during 
sacrifice. (D) Immunoblot analysis of eWAT SVF. Each SVF sample was extracted from eWAT of 2 mice in each group. Data were presented as mean±SEM. * (p < 0.05) and ** 
(p < 0.01) compared with the control group (bar with white squares). 
 
These eWATs were cultured ex vivo and 
stimulated with LPS and FFA. The release of 
cytokines, including IL-1β, IL-18, IL-6, and TNFα, 
from eWAT in VLN-IV mice was decreased, 
compared to control mice (Figure 7A). The cytokines 
released from eWAT in VLN-OG mice tended to be 
lower than in control mice but did not reach statistical 
significance for most of them (Figure 7A). At the 
molecular level, both orally and intravenously 
administered GC-VLNs decreased transcription of the 
Nlrp3, Pycard, Casp1, Il1b, Tnf, and Il6 genes in eWAT, 
but had no effects on mRNA level of the Nek7 gene 
(Figure 7B-C). At the protein level, the cleaved Casp1 
and inflammasome components, including NLRP3, 
Casp1, and ASC, were much lower in the SVF of 
GC-VLN treated mice (Figure 7D). Altogether, it 
seems that both IV- and OG-administered GC-VLNs 
improved metabolic health and decreased NLRP3 
inflammasome activity and inflammation in 
diet-induced obese mice. 
Lipids in GC-VLNs suppressed activation of 
the NLRP3 inflammasome 
Next, we tried to determine which category of 
biomolecules in GC-VLNs was critical in mediating 
the anti-NLRP3 inflammasome function. GC-VLNs 
were first heat-treated to denature proteins in the 
nanoparticles. Such heat-treated GC-VLNs retained 
the ability to suppress the NLRP3 inflammasome in 
LPS-primed BMDMs activated by ATP or FFA (Figure 
8A and D), indicating that proteins in GC-VLNs were 
not the key molecules mediating anti-inflammasome 
function. Second, GC-VLNs were subjected to 
sonication plus RNase treatment to deplete RNAs. 
The integrity of these membrane-bound nanoparticles 
was compromised with the sonication treatment and, 
as a result, RNase could easily enter to degrade RNAs 
[19]. Approximately 98% of RNAs in GC-VLNs were 
removed by this treatment (Figure S9). The 
RNA-depleted GC-VLNs still suppressed the NLRP3 
inflammasome (Figure 8B and E), implying that the 
majority of RNAs in GC-VLNs were not critical in 
suppressing NLRP3 inflammasome activity. Since 
neither proteins nor RNAs were critical in inhibiting 
the NLRP3 inflammasome, it was likely that lipids in 
GC-VLNs played a role in suppressing activation of 
the NLRP3 inflammasome. To directly assess the role 
of lipids in GC-VLNs, total lipids in GC-VLNs were 
purified and re-assembled into liposomes, which 
mimic the membrane-enclosed structure of GC-VLNs. 
Such liposomes potently inhibited the NLRP3 
inflammasome activated by ATP or FFA (Figure 8C 
and F). Therefore, lipids in GC-VLNs are responsible 
for suppressing activation of the NLRP3 
inflammasome. 






Figure 8. Lipids from GC-VLNs suppressed NLRP3 inflammasome activation. (A and D) GC-VLNs were heated at 95 °C for 10 min to denature proteins. 9×1010 
mL-1 of regular (reg) or heated GC-VLNs were preincubated with BMDMs for 16 h, followed by NLRP3 inflammasome activation using LPS+ATP (A) or LPS+FFA (D). (B and E) 
GC-VLNs were added with 10 µg mL-1 of RNase, subjected to bath sonication at room temperature for 1.5 h, and incubated at 37 °C for an additional 1 h to degrade RNAs inside 
the nanoparticles (S/R-treated). 9×1010 mL-1 of regular (reg) or RNA-depleted (S/R-treated) GC-VLNs were used. (C and F) Lipids were extracted from GC-VLNs and 
reassembled into liposomes. 9×1010 mL-1 of regular (reg) GC-VLNs or liposomes from GC-VLN lipids were preincubated with BMDMs for 16 h, followed by NLRP3 
inflammasome activation using LPS+ATP (C). In (F), different doses of liposomes from GC-VLN lipids were preincubated with cells for 16 h, followed by LPS and FFA treatment 
to activate the NLRP3 inflammasome. Results were expressed as mean±SEM from three independent experiments. * (p < 0.05) and ** (p < 0.01) compared with LPS+ATP group 
(black bar). 
 
Specific phospholipid was identified to inhibit 
NLRP3 inflammasome activity 
During our studies, we noticed that GC-VLNs 
from the local grocery shop did not consistently 
suppress NLRP3 inflammasome activation. To ensure 
consistency and freshness of raw material, garlic chive 
seeds were purchased and plants were grown in a 
greenhouse facility; plant leaves were freshly 
harvested for VLN extraction. However, the 
anti-inflammatory effects of GC-VLNs still varied – 
sometimes they exerted strong anti-inflammasome 
functions (active), but sometimes they lost such effects 
(inactive) (Figure S10A-B). There was no significant 
size difference between active and inactive GC-VLNs 
(Figure S10C). The morphology and vesicular- 
structure of inactive GC-VLNs (Figure S10D) were 
similar to those of active GC-VLNs (Figure 1B). 
Generally, GC-VLNs obtained in the winter-spring 
season, but not in summer-fall, had potent 
anti-inflammasome function, although the underlying 
mechanism was not clear. For all the studies 
mentioned above, we always used active GC-VLNs. 
Typically, one big batch of GC-VLNs was extracted 
and tested for their anti-inflammasome function in 
BMDMs. If we observed strong anti-inflammasome 
function, the batch would be aliquoted, stored at -80 
°C, and used for in vitro and in vivo studies. 
Anti-inflammasome functions of GC-VLNs were 
stable after -80 °C storage but still were subjected to 
periodical cell culture tests to ensure their 
bioactivities. The inactive GC-VLNs were usually 
discarded and used only as negative controls in the 
GC-VLN comparison analysis. 
After lipids were identified as bioactive 
molecules in GC-VLNs, total lipids were extracted 
from active and inactive GC-VLNs and reassembled 
into liposomes. Only liposomes prepared from active 
GC-VLNs, but not from inactive GC-VLNs, showed 
strong inhibitory effects on the downstream events of 
NLRP3 inflammasome activation, including Casp1 
autocleavage (Figure 9A), IL-1β release (Figure 9B), 
and IL-18 release (Figure 9C). Liposomes from active 
GC-VLNs also retained inhibitory effects on the 
secretion of both IL-6 and TNFα, but liposomes from 
inactive GC-VLNs lost such functions (Figure 
S11A-B). The distinct anti-inflammatory properties of 
lipids from active and inactive GC-VLNs provided 
good sources that allowed us to compare their 
composition and identify specific active biomolecules. 
To compare the composition of lipids from active 
and inactive GC-VLNs, total lipids from five 
replicates of these two sources were extracted and 
subjected to lipidomics analysis. The lipid profiles of 
active and inactive GC-VLNs were very distinct 
(Figure 9D and Table S2). Strikingly, the level of 
phosphatidylcholine (PC) in active GC-VLNs was 
much higher than the level in inactive GC-VLNs (43% 





vs 26%). Figure 9E highlights eight PC species that 
were most abundant in active GC-VLNs and whose 
levels in active GC-VLNs were meanwhile at least 
1.3-fold higher than levels in inactive GC-VLNs. 
Among these PCs, PC(34:2) and PC(36:4) were most 
abundant in active GC-VLNs, and the level of 
PC(34:1) increased most significantly in active 
GC-VLNs compared to inactive GC-VLNs. Therefore, 
these three PC lipids were selected for further 
evaluation. Isoform analysis revealed that in active 
GC-VLNs, PC(34:2) was 1-palmitoyl-2-linoleoyl-sn- 
glycero-3-phosphocholine (PC(16:0/18:2)); PC(36:4) 
was dominantly 1,2-dilinoleoyl-sn-glycero-3- 
phosphocholine (DLPC, PC(18:2/18:2)), with a tiny 
amount of 1-oleoyl-2-linolenoyl-sn-glycero-3- 
phosphocholine; and PC(34:1) was 1-palmitoyl-2- 
oleoyl-sn-glycero-3-phosphocholine (PC(16:0/18:1)). 
To directly test their roles in NLRP3 
inflammasome activation, PC(34:2), PC(34:1), and 
DLPC (the dominant isoform of PC(36:4) in GC- 
VLNs) were purchased and assembled into liposomes 
to test their anti-inflammasome activity. Liposomes 
prepared from the PC(36:4) isoform DLPC, but not 
liposomes from control 1,2-dipalmitoyl-sn-glycero-3- 
phosphocholine (PC (32:0)), PC(34:1), or PC(34:2), 
potently inhibited Casp1 autocleavage (Figure 10A) 
and IL-1β release (Figure 10B) upon NLRP3 
inflammasome activation in BMDMs. SEM analysis 
showed that liposomes from PC(36:4) were 
homogeneous individual nanoparticles (Figure S12A), 
and NTA showed that these liposomes were 
approximately 100 nm in diameter (Figure S12B). 
DLPC-derived liposomes dose-dependently inhibited 
Casp1 autocleavage (Figure 10C-D), IL-1β release 
(Figure 10E and G), and IL-18 secretion (Figure 10F 
and H) when the NLRP3 inflammasome was 
activated by ATP or FFA in LPS-primed BMDMs. 
DLPC-derived liposomes also inhibited secretion of 
both IL-6 and TNFα (Figure S13A-D). 
Discussion 
In this study, we found that VLNs were present 
in commonly consumed Allium vegetables. VLNs 
from garlic chives, but not other Allium vegetables we 
tested, potently suppressed NLRP3 inflammasome 
activation in primary macrophages. Local injection of 
GC-VLNs alleviated liver damage and reduced 
inflammation in the mouse model of acute liver 
injury. Long-term weekly administration of GC-VLNs 
through oral gavage or intravenous injection 
improved metabolic health and reduced chronic 
inflammation in diet-induced obese mice. The 
phospholipid DLPC was identified in GC-VLNs to 
mediate anti-inflammasome functions. 
 
 
Figure 9. Lipids from active and inactive GC-VLNs were subjected to lipidomic analysis. (A-C) BMDMs were preincubated with liposomes prepared from lipids of 
active or inactive GC-VLNs, followed by NLRP3 inflammasome activation. (A) Immunoblot analysis of Casp1 p10 in cell lysates. (B) Levels of IL-1β in the culture media. (C) Levels 
of IL-18 in the culture media. Results were expressed as mean±SEM from three independent experiments. * (p < 0.05) and ** (p < 0.01) compared with LPS+ATP group (black 
bar). (D) Lipidome comparison of active and inactive GC-VLNs. PC: phosphatidylcholine; PE: phosphatidylethanolamine; PA: phosphatidic acid; PG: phosphatidylglycerol; MGDG: 
monogalactosyldiacylglycerol; DGDG: digalactosyldiacylglycerol. (E) Abundance and fold change of top eight PC species in active GC-VLNs. 






Figure 10. DLPC was identified to suppress NLRP3 inflammasome activation. (A-B) BMDMs were preincubated with liposomes prepared from PC lipids for 16 h, 
followed by LPS+ATP treatment to activate the NLRP3 inflammasome. (A) Immunoblot analysis of Casp1 p10 in cell lysates. (B) Levels of IL-1β in the culture media. (C-H) 
BMDMs were preincubated with DLPC liposomes (PC(36:4)) for 16 h, followed by LPS+ATP or LPS+FFA treatment to activate the NLRP3 inflammasome. Cell lysates were 
subjected to immunoblot analysis and cell-free media were used for cytokine measurement. Results were expressed as mean±SEM from three independent experiments. * (p < 
0.05) and ** (p < 0.01) compared with LPS+ATP group or LPS+FFA group (black bar). 
 
Garlic chive (A. tuberosum) is native to Shanxi 
province located in north-central China and is 
consumed by people in many Asian countries, 
including China, Korea, Japan, and India [49]. This 
Allium species has been reported to have anti-cancer, 
anti-oxidant, and anti-inflammatory functions [49], 
suggesting the medicinal potential of this plant. Over 
40 compounds, including organosulfur compounds 
and flavonoids often found in other Allium vegetables, 
have been identified in garlic chive [50]. Among its 
compounds, thiosulfinates were shown to induce 
apoptosis of colon cancer cells and tuberoside M 
suppressed proliferation of leukemia cells [51,52]. 
Studies on the anti-inflammatory function of garlic 
chives are scarce. Here, we identified a new bioactive 
agent in garlic chive – GC-VLN, membrane-enclosed 
vesicle-like nanoparticles containing proteins, RNAs, 
and lipids (Figure 1). Proteomics analysis of proteins 
in GC-VLNs (Table S1) demonstrated the presence of 
a series of plasma membrane proteins and 
membrane-associated cytosolic proteins, indicating 
the vesicle-like nature of GC-VLNs, based on the 
guidelines from Minimal Information for Studies of 
Extracellular Vesicles 2018 (MISEV2018) [53]. These 
GC-VLNs potently inhibited NLRP3 inflammasome- 
mediated inflammation in cell culture and animal 
disease models (Figures 2, 3, 5-7). Therefore, our 
research revealed that garlic chive’s newly identified 
component GC-VLNs demonstrated a new bioactivity 
– an anti-NLRP3 inflammasome function, which 
significantly contributes to the basic understanding of 
how garlic chive exerts its anti-inflammatory function. 
Further investigation revealed that phospholipid 
DLPC in GC-VLNs mediated the anti-NLRP3 
inflammasome function (Figure 8-10). Lipids have 
been found to either impede or activate the NLRP3 
inflammasome. Omega-3 polyunsaturated fatty acids, 
such as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), inhibit activation of the 
NLRP3 inflammasome [54], whereas saturated fatty 
acids, such as palmitic acid, activate the NLRP3 
inflammasome [14]. Oxidized PCs, including 
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphoc
holine [55] and 1-O-alkyl-2-acetyl-sn-glycero-3- 
phosphocholine (also called platelet-activating factor) 
[56] activate the NLRP3 inflammasome. Our research 
demonstrated an unprecedented anti-NLRP3 
inflammasome function of the phospholipid DLPC in 
GC-VLNs. Phospholipid PCs have been regarded as 
membrane bricks since they are the most abundant 
phospholipids in plasma membranes and subcellular 
organelles in eukaryotic cells [57]. Interestingly, some 
PCs have been identified to serve directly as signaling 
molecules. For example, 1-palmitoyl-2-oleoyl-sn- 
glycerol-3-phosphocholine has been identified as the 
endogenous ligand for the nuclear receptor 
peroxisome proliferator-activated receptor α (PPARα) 
[58]. PPARδ in liver regulates the rhythmic level of 






serum, which modulates fatty acid use in muscle [59]. 
DLPC has been shown to decrease the release of TNFα 
in the LPS-treated murine macrophage-like 
RAW264.7 cell line [60], as well as in LPS-treated 
Kupffer cells isolated from rats fed an 
alcohol-containing diet [61]. A purified extract of 
soybean lecithin (94-96% PC), which contains 40-52% 
DLPC, protects baboons from alcohol-induced fibrosis 
and cirrhosis [62]. Our research revealed another 
interesting function of DLPC − it inhibits NLRP3 
inflammasome activity. 
Current NLRP3 inflammasome-related therapies 
in clinical practice target its cleavage product, IL-1β, 
using neutralizing IL-1β antibodies (Gevokizumab or 
Canakinumab), IL-1 receptor antagonist (Anakinra), 
or the soluble decoy IL-1 receptor (Rilonacept) [63]. 
Anakinra, Rilonacept, and Canakinumab have been 
approved to treat cryopyrin-associated auto-
inflammatory syndrome patients [63], and Anakinra 
has been found to reduce inflammation and plasma 
glucose levels and enhance insulin secretion in 
diabetic patients in clinical trials [64]. While cytokine- 
targeting therapies appear to be promising, they 
target only IL-1β, not IL-18 or other downstream 
events of the NLRP3 inflammasome. The treatments 
are costly and sometimes cause adverse effects such as 
redness, bruising, or pain at the injection site. Some 
small-molecule chemicals, such as MCC950 [65] and 
Bay 11-7082 [66], suppressed assembly and activation 
of the NLRP3 inflammasome and reduced the severity 
of NLRP3 inflammasome-driven disorders, such as 
cryopyrin-associated autoinflammatory syndrome or 
experimental autoimmune encephalomyelitis in mice. 
Impeding assembly and activation of the NLRP3 
inflammasome blocks all its downstream pathways 
and theoretically offers greater therapeutic promise to 
treat NLRP3 inflammasome-driven diseases. 
However, the bioavailability, potency, and long-term 
safety of these chemicals in humans have not been 
well characterized. 
GC-VLNs identified in this study potently 
inhibited all the downstream pathways of the NLRP3 
inflammasome through blockage of its assembly and 
activation (Figure 2, S3, and S4). When administered 
locally or systemically in mice, GC-VLNs effectively 
suppressed acute or chronic inflammation in different 
disease models (Figure 3, 5-7), suggesting the 
promising efficacy of these dietary nanoparticles in 
vivo. In the obesity study, three months of intravenous 
or oral administration of GC-VLNs had no 
detrimental effects on the general health of mice 
(Figure 5). Orally given GC-VLNs can be absorbed 
through the digestive tract and accumulated in kidney 
and eWAT in obese mice. Intravenously administered 
GC-VLNs also significantly accumulated in kidney 
and eWAT, implying the possibility of intrinsic tissue 
selection of GC-VLNs after their absorption (Figure 4). 
Dietary VLNs have been shown to have distinct 
biodistribution in vivo. For example, grape VLNs 
accumulated in intestinal stem cells [25], grapefruit 
VLNs were detected in liver [24], and ginger VLNs 
were found in the intestinal macrophages [67], liver, 
and mesenteric lymph nodes [24] after oral gavage in 
mice. The enrichment of PC in grapefruit VLNs was 
critical in promoting the accumulation of these 
nanoparticles in the liver [68]. Specific integrin 
proteins of tumor-derived extracellular vesicles 
enabled these vesicles to target specific tissues and 
induced metastasis in these tissues [69]. The enriched 
phosphatidylserine of tumor-derived extracellular 
vesicles facilitates the recognition and uptake of these 
vesicles by macrophages [70]. Therefore, the unique 
biodistribution pattern of GC-VLNs reiterates the 
notion that the lipid composition and/or specific 
surface proteins of extracellular vesicles and dietary 
VLNs may mediate their specific uptake by target 
cells and tissues. Therefore, as a natural nano-carrier, 
GC-VLN’s unique biodistribution, high efficacy, and 
long-term safety in vivo demonstrated in our research 
suggest their high therapeutic potential. In addition, 
garlic chives generate abundant GC-VLNs (around 
3.4×1011 g-1, Figure S1), can be easily cultivated at low 
cost, and have been safely consumed as a daily 
vegetable in many Asian countries for centuries 
[26,49]. All these properties should facilitate their 
translational application. Identification of DLPC as an 
active anti-inflammasome component in GC-VLNs 
would facilitate quality control of GC-VLNs, as well 
as guide the grow-condition studies of garlic chive to 
stabilize the anti-inflammatory function of GC-VLNs 
in the future. However, as a pure lipid, DLPC alone 
(nor its derived liposomes) lacks the specific lipid 
composition and specific surface proteins of 
GC-VLNs and therefore is not likely to share 
GC-VLNs’ unique biodistribution in vivo. Further 
studies on the bioavailability, efficacy, and safety of 
DLPC in vivo are warranted. 
Our previous studies have identified that VLNs 
from ginger, shiitake mushroom, and honey inhibit 
the NLRP3 inflammasome [19,20,27]. A microRNA 
miR-4057 was identified in honey VLNs in inhibiting 
NLRP3 inflammasome activation [20], but the active 
components in ginger- and shiitake mushroom- 
derived VLNs have not been elucidated. Our current 
study identified VLNs from garlic chive – GC-VLNs – 
with anti-inflammasome function and also revealed 
that DLPC in GC-VLNs strongly suppresses the 
NLRP3 inflammasome. Although GC-VLNs shared 
the same anti-NLRP3 inflammasome as three VLNs in 





our previous studies, this research has its own 
importance and novelty as reasoned below: 
1) In each of our studies, we screened 5-10 foods 
from vegetables, fruits, spices, mushrooms, and 
bee-related products. In our unpublished pilot 
studies, we have screened more dietary VLNs. In total 
we have tested VLNs from over 50 dietary sources. So 
far we have found only four VLNs that inhibit the 
NLRP3 inflammasome. Therefore, finding of 
GC-VLNs with anti-inflammasome function, together 
with our previous studies, establishes an implicit 
consensus that anti-inflammasome function is unique 
and possessed only by specific dietary VLNs. 2) This 
study was designed to thoroughly assess the 
therapeutic potential of GC-VLNs in combating acute 
or chronic inflammation using acute liver failure and 
obesity disease models. Our previous studies mainly 
used cell culture or acute liver damage models to 
provide proof-of-concept evidence for the anti- 
inflammatory functions of dietary VLNs [19,20,27]. 
Other dietary VLN studies have not examined the role 
of any dietary VLNs in obesity or acute liver failure 
disease models. Therefore, our current study revealed 
the possible new therapeutic application of dietary 
VLNs in the prevention or treatment of chronic 
inflammation in obesity. 3) This research identified 
DLPC as an active component of GC-VLNs, compared 
to microRNAs as the active components of honey- 
derived VLNs [20], indicating that GC-VLNs have a 
completely new and different mechanism to inhibit 
the NLRP3 inflammasome. Our two studies together 
corroborate that nature develops diverse yet elegant 
mechanisms to curb dysregulated inflammation in 
humans. 4) This study highlights the important yet 
underappreciated functions of lipids in dietary VLNs. 
Many dietary ELN studies have demonstrated the 
importance of microRNAs or other components in 
dietary VLNs. For example, microRNAs in ginger 
VLNs regulate the composition of the gut microbiota 
and their functions [68]. Depletion of microRNAs in 
milk VLNs led to altered expression of immune- 
related genes and exacerbated intestinal inflammation 
in Mdr1a-deficient mice [71]. Phytochemical shogaol 
in ginger VLNs induced transcription of detoxifying/ 
antioxidant genes and protected mice from alcohol- 
induced liver damage [24]. The functions of lipids in 
dietary VLNs are only beginning to be appreciated. 
PA(34:2) from ginger-derived VLNs was reported to 
specifically inhibit the growth of an oral pathogen, 
Porphyromonas gingivalis, through interaction with the 
outer membrane protein HBP35 of this pathogenic 
bacterium and suppressing expression of some of its 
virulence-related genes [72]. Our study uncovered 
another lipid DLPC from GC-VLNs with anti- 
inflammatory function. In the current study, we 
examined only the functions of DLPC in inhibiting the 
NLRP3 inflammasome. It is possible that other lipid 
species in GC-VLNs could contribute to the anti- 
inflammasome functions of GC-VLNs, which will be 
further investigated in the future. 
In conclusion, GC-VLNs and their active 
component DLPC with potent anti-inflammasome 
activity represent a new type of bioactive agent with 
potential to treat NLRP3 inflammasome-driven 
diseases. In the future, it would be also important to 
elucidate the precise molecular mechanism by which 
GC-VLNs and DLPC inhibit the NLRP3 
inflammasome. 
Materials and Methods 
Macrophage culture 
BMDMs from C57BL/6J mice were prepared as 
described [73]. Bone marrow cells from mice were 
grown in RPMI medium(Corning, Tewksbury, MA, 
USA) containing 10% fetal bovine serum (FBS; Atlanta 
Biologicals, Minneapolis, MN, USA, S1150), 20% L929 
cell-conditioned medium, 50 μg mL-1 PenStrep 
(Corning, Tewksbury, MA, USA), 2 mM glutamine 
(Corning), 1 mM sodium pyruvate (Corning), and 10 
mM HEPES buffer (Corning). To assess the regulatory 
role of dietary VLNs in NLRP3 inflammasome 
activation, BMDMs were preincubated with VLNs for 
16 h, then incubated with 10 ng mL-1 LPS (InvivoGen, 
San Diego, CA, USA, tlrl-peklps) for 3 h and 1000 µM 
sodium palmitate for 12 h (Sigma, St. Louis, MO, 
USA), or 2.5 mM ATP for 30 min (Sigma), or 5 μM 
nigericin for 30 min (Enzo Life Sci, Farmingdale, NY, 
USA), or 0.5% v/v alum for 5 h (ThermoFisher 
Scientific, Waltham, MA, USA) to activate the NLRP3 
inflammasome. To activate the AIM2 inflammasome, 
BMDMs were incubated with LPS for 3 h, followed by 
transfection with calf DNA (Sigma, D3664), 2 µg for 
each well for 2 h. At the end of stimulation, the cells 
were directly lysed in SDS loading buffer; cell culture 
media were collected, centrifuged at 300 ×g for 5 min 
to remove any cell debris, and subjected to cytokine 
measurement or immunoblot analysis. 
Mice 
C57BL/6J and Nlrp3A350VneoR mice were 
purchased from Jackson Laboratory (Bar Harbor, ME, 
USA) and maintained in a specific pathogen-free 
facility. Animal experiments were approved by the 
Institutional Animal Care and Use Committee of 
University of the Nebraska-Lincoln (Project ID 1421, 
1973, and 1936). For the preparation of peritoneal 
macrophages, 3% (v/v) brewer thioglycolate medium 
(Sigma) was intraperitoneally injected into C57BL/6J 
mice; 3 days later, peritoneal macrophages were 





collected from the peritoneal fluid. To study the 
biodistribution of GC-VLNs, GC-VLNs covalently 
labeled with fluorescence dye in near infrared ranges 
using ExoGlow-Vivo EV labeling kit (System 
Biosciences, Palo Alto, CA, USA) and free dye control 
from the same kit were orally or intravenously 
administered to lean 8-week-old male C57BL/6J mice. 
6 h later, the mice were sacrificed to harvest a variety 
of tissues, which were assessed for fluorescence 
signals using the Odyssey Clx imaging system 
(LI-COR Biosciences, Lincoln, NE, USA). The same 
labeled GC-VLNs were intravenously or orally given 
to 21-week-old obese male C57BL/6J mice, which 
were fed with a HFD (Bio-Serv, Flemington, NJ, USA, 
F3282, 60% of fat calories) for 15 weeks. The mice were 
sacrificed after 6 h to assess the fluorescence signals in 
their tissues. 
For the acute liver injury model, 8-week-old 
male C57BL/6J mice were intraperitoneally 
administered GC-VLNs at a dose of 1×1010 g-1. After 
48 h, mice were intraperitoneally injected with 15 µg 
kg-1 LPS (Sigma, L2630) and 500 mg kg-1 GalN (Sigma, 
34539) to induce acute liver injury. After 6 h, animals 
were sacrificed to collect serum and livers for further 
analysis. The expression of the Nlrp3 gene is disrupted 
in Nlrp3A350VneoR mice, which therefore serves a 
Nlrp3-deficient mouse strain [7]. This mouse strain 
was crossed with C57BL/6J mice to generate 
heterozygous mice, which were used to generate wt 
and Nlrp3-/- littermates. 8-week-old wt and Nlrp3-/- 
female littermates were subjected to LPS/GalN 
injection and sacrificed after 6 h. 
For the diet-induced obesity study, 8-week-old 
male C57BL/6J mice were fed with a HFD (Bio-Serv) 
and randomly separated into three groups. When the 
HFD feeding started, the mice in the control group 
received PBS weekly through both IV and OG, the 
mice in the VLN-IV group were given 1×1010 g-1 
GC-VLNs through IV and PBS through OG, and the 
mice in the VLN-OG group were administered 1×1010 
g-1 GC-VLNs through OG and PBS through IV to 
ensure all the mice were treated with the same 
administration routes. Body weight of the mice was 
measured weekly. After the 11-week treatment, the 
mice were kept individually in a Phenomaster/ 
Labmaster caging system (TSE Systems, Chesterfield, 
MO, USA) for 48 h. The first 24 h was the adaption 
period, and the data from the last 24 h were used for 
calculating food intake, water intake, and movement 
counts. At the end of the 13-week treatment period, 
the mice were subjected to an ipGTT. Briefly, the mice 
were fasted for 6 h, followed by intraperitoneal 
injection of 1g kg-1 glucose (Sigma). The levels of 
blood glucose were measured every 30 min over a 
period of 150 min using a Bayer Contour Next blood 
glucose monitoring system (Parsippany, NJ, USA). 
After 15 weeks of treatment, the mice were sacrificed 
to collect serum and eWAT for further analysis. 
Garlic chive 
The seeds of garlic chive (A. tuberosum) were 
purchased from Richters Herbs (Goodwood, ON, 
Canada) and grown in the greenhouse facility at the 
University of Nebraska-Lincoln (Lincoln, NE, USA). 
The temperature in the greenhouse facility was 
controlled between 24 °C and 27 °C. Natural sunlight 
was the main light source, supplemented with three 
1000-watt high-pressure sodium lights turned on at 6 
AM and off at 8 PM to ensure 14 h of light/day. The 
plants were grown in a mixture of peat, soil, sand, and 
vermiculite at the ratio of 5:3:2.5:2.5. The garlic chive 
leaves were harvested bi-weekly to ensure that 
maturation levels of leaves were comparable when 
they were used to extract VLNs. 
Isolation and characterization of VLNs 
Bulbs of garlic and purple or white onion and 
leaves of leek, scallion, and garlic chive were 
purchased from local grocery shops, washed, and 
minced. 2-5 g of minced materials were soaked in cold 
PBS and shredded for 15 s in a kitchen blender. The 
juice was filtered through a mesh sheet and 
centrifuged at 500 ×g for 10 min, 2000 ×g for 20 min, 
and 10,000 ×g for 30 min at 4 °C. The final supernatant 
underwent ultracentrifugation at 100,000 ×g for 2 h at 
4 °C using a SW-32TI rotor in an Optima XE-90 
ultracentrifuge (Beckman Coulter, Brea, CA, USA). 
The nanoparticle pellets were washed with cold PBS, 
resuspended in PBS, and centrifuged at 10,000 ×g for 
10 min at 4 °C to remove any aggregates. VLNs in PBS 
were passed through a 200 nm Acrodisc filter (Pall 
Laboratory, Port Washington, NY, USA) to sterilize 
the solution. For TEM and SEM analysis, VLNs were 
further purified using a sucrose gradient. Briefly, the 
nanoparticles in PBS were loaded on sucrose 
gradients of 8%, 30%, and 60% (w/v) and underwent 
ultracentrifugation at 150,000 ×g for 16 h at 4 °C. The 
fractions enriched with GC-VLNs were collected, 
diluted in PBS, and subjected to ultracentrifugation at 
100,000 ×g for 2 h at 4 °C. Characterization of VLNs, 
including size and yield measurement, biomolecule 
separation, and RNA depletion of GC-VLN, was 
conducted as described [19,27]. For the detergent 
treatment of VLNs, VLN solutions were added with 
Triton X-100 (Sigma) at different concentrations, 
vortexed for 30 s, kept at room temperature for 30 
min, and subjected to particle number measurement 
using a NanoSight NS300 instrument (Malvern, 
Westborough, MA, USA). 





Labeling and uptake of GC-VLNs 
The lipophilic dye DiI (2 µM) was gently mixed 
with GC-VLNs in PBS for 30 min at 37 °C to label the 
membrane lipids. 35-fold more PBS was added to the 
mixture, and it was subjected to ultracentrifugation at 
100,000 ×g for 2 h at 4 °C to remove free dye. The 
obtained GC-VLNs were resuspended in PBS and 
incubated at 37 °C for 1 h, ready to be incubated with 
BMDMs. Proteins and RNAs inside GC-VLNs were 
labeled with ExoGlow protein EV labeling kit and 
ExoGlow RNA EV labeling kit (System Biosciences), 
respectively, per manufacturer’s protocols. BMDMs 
were incubated with the fluorescence-labeled 
GC-VLNs for 16 h or the indicated time in the 
time-course experiment, washed with PBS 4 times, 
and fixed with 4% paraformaldehyde (Sigma). Images 
were taken using an A1R-Ti2 confocal system (Nikon, 
Melville, NY, USA). 
For the distribution studies of GC-VLNs in mice, 
fluorescence dye from ExoGlow-Vivo EV labeling kit 
(EXOGV900A-1, System Biosciences) was used to 
label GC-VLNs at the ratio of 60×1010 nanoparticles : 1 
µl dye, per manufacturer’s protocol. The labeled 
GC-VLNs were resuspended in 30 mL of PBS and 
ultra-centrifuged at 100,000 ×g for 2 h at 4 °C to 
remove the free dye. The wash step was repeated two 
times. The obtained GC-VLNs covalently linked to the 
dye were given to mice through oral gavage or 
intravenous injection. 
Electron microscopy 
SEM analysis of active GC-VLNs and liposomes 
was carried out for evaluation of particle shape and 
size range [19,20]. GC-VLNs were fixed with 2.5% 
glutaraldehyde and 1% tannic acid in 0.1 M 
cacodylate buffer (pH7.2) for 1 h and collected using a 
MF-Millipore membrane filter (50 nm pore size; 
Millipore Sigma). The membrane was briefly dried, 
mounted onto a SEM stub, further dried in the air for 
2 h, and sputter-coated with a 2-3 nm thick layer of 
chromium using a Desk V sputter (Denton Vacuum, 
Moorestown, NJ, USA). SEM images of GC-VLNs 
were obtained using a Hitachi S4700 Filed-Emission 
SEM (Hitachi, Santa Clara, CA, USA). 
Ultrastructure TEM was carried out for 
conformational and vesicular analysis of active and 
inactive GC-VLNs [20]. Pellets of GC-VLNs were 
incubated with 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer (pH7.2) at room temperature for 1 h. 
After two washes with the same buffer, the samples 
were post-fixed with 1% osmium tetroxide in 
deionized water at room temperature for 1 h to fix 
lipids. Fixed VLNs were rinsed in deionized water 
three times, followed by a dehydration process using 
a graduated ethanol series, and embedded in Spurr 
medium mix (Electron Microscopic Sciences, Fort 
Washington, PA, USA). A Leica UC7 ultramicrotome 
(Allendale, NJ, USA) was used to cut the samples to 
obtain ultrathin sections (~90 nm), which were 
stained with uranyl acetate and lead citrate. 
Ultrastructural images were collected using a Hitachi 
H7500 TEM with a bottom-mount AMT digital 
camera. 
Lipid extraction, lipidomics analysis, and 
liposome preparation 
All lipid extraction reagents were high- 
performance liquid chromatography (HPLC) grade. 
Chloroform (Sigma) was supplemented with 0.01% 
butylated hydroxytoluene (Sigma) to protect 
polyunsaturated lipids. 0.8 parts GC-VLNs in PBS 
were added with 1 part chloroform and 2 parts 
methanol in a glass tube, followed by vigorous 
shaking. The mixture was added with 1 part 
chloroform and 1 part water, vigorously shaken, and 
centrifuged at 1000 ×g for 10 min. The lower layer 
containing chloroform and lipids was collected in a 
clean glass tube. The leftover solution was added with 
1 part chloroform, mixed well, and centrifuged to 
collect residue lipids. The chloroform extraction was 
repeated one more time. All the chloroform layers 
containing lipids were combined, washed once with 
0.25 part of 1 M KCl solution, and once more with 0.25 
part of water. The organic phase containing lipids was 
dried at 60 °C, with a stream of nitrogen gas blowing 
over the lipid solution. The dried lipids of five 
replicates of inactive and active GC-VLNs were sent 
to the Lipidomics Research Center at the Kansas State 
University (Manhattan, KS, USA), where analysis was 
conducted using a direct-infusion electrospray 
ionization triple quadrupole 4000QTrap mass 
spectrometer (Applied Biosystems, Foster City, CA, 
USA) to determine the lipid composition or lipid 
isoforms [74]. Lipid composition was presented as a 
percentage of the total signal for the molecular 
species, determined after normalizing the signals to 
internal standards of the same lipid class. 
To assemble lipids from GC-VLNs into 
liposomes, 500 µl of distilled water were added to the 
dried lipids, and the mixture was sonicated for 5 min 
in a bath sonicator (Branson Ultrasonics, Danbury, 
CT, USA) and further sonicated using a S-450D digital 
sonifier unit (Branson Ultrasonics) in the mode of 10 s, 
on and 20 s off for a total of 3 min. The phospholipids 
PC(32:0), PC(34:1), PC(34:2), and DLPC were 
purchased from Sigma, dissolved in chloroform, 
aliquoted, and kept at -20 °C. To prepare liposomes 
from these lipids, one aliquot was dried at 60 °C ,with 
a stream of nitrogen gas blowing over the lipid 
solution, and the dried lipids were suspended in 0.9% 





saline or PBS. The mixture was vigorously vortexed 
every 15 min for a total of 30 min and extruded 
through a NanoSizer mini extruder using 100 nm 
membrane (T&T Scientific, Knoxville, TN, USA) 
following the manufacturer’s instructions. 
Proteomics analysis of GC-VLNs 
The pellets of purified GC-VLNs were lysed in 
NuPAGE™ LDS sample buffer (ThermoFisher 
Scientific, Waltham, MA, USA) and the lysate was run 
in a Bolt™ 12% Bis-Tris Plus gel for 10 min, followed 
by in-gel digestion with trypsin. The obtained 
peptides were subjected to LC-MS/MS analysis using 
a RSLCnano system (ThermoFisher Scientific) 
coupled to a Q-Exactive HF mass spectrometer 
(ThermoFisher Scientific). The resulting proteomics 
data were analyzed with Mascot v 2.6.1 (Matrix 
Science, Boston, MA, USA) using the common 
contaminants database cRAP (123 entries, 
www.theGPM.org) and the Uniprot entries for 
viridiplantae (retrieved on 04/30/2019, 7108828 
entries). The identified peptides and proteins were 
validated using Scaffold v4.8.9 (Proteome Software 
Inc., Portland, OR). For peptides, if they reached 
greater than 80.0% probability by the Peptide Prophet 
algorithm [75] with Scaffold delta-mass correction, 
their identifications were accepted. For proteins, if 
they reached 99.0% probability by the ProteinProphet 
algorithm [76] and contained at least 2 identified 
peptides, their identifications were established. 
ASC immunofluorescence staining and 
oligomer analysis 
ASC immunofluorescence staining was done as 
described [19]. 1:200 anti-ASC rabbit antibody 
(Adipogen, San Diego, CA, USA, AG25B0006C100) 
and 1:200 Alexa Fluor-594-conjugated secondary 
antibody (Invitrogen, Carlsbad, CA, USA, A-11037) 
were used for ASC immunofluorescence staining. For 
the ASC oligomer analysis, BMDMs were lysed 20 
min with PBS containing 0.5% Triton X-100, 
EDTA-free protease inhibitor cocktails (Roche, 
Indianapolis, IN, USA) and centrifuged at 6,000 ×g at 
4 °C for 15 min. The Triton-soluble supernatant was 
collected for immunoblot analysis. The 
Triton-insoluble pellets were rinsed with PBS twice, 
resuspended in 300 µl PBS containing 2 mM of 
disuccinimidyl suberate (ThermoFisher Scientific) to 
crosslink the ASC oligomers at 37 °C for 30 min, and 
centrifugated at 6,000 ×g at 4 °C for 15 min. The pellets 
containing the crosslinked ASC oligomers were 
resuspended in SDS loading buffer for immunoblot 
analysis. 
Tissue H&E staining and liver injury marker 
measurement 
A small piece of liver or eWAT was soaked in 
10% formalin solution (VWR, Radnor, PA, USA) 
during mouse sacrifice. After overnight fixing, the 
tissues were transferred to cold PBS and submitted to 
the Veterinary Diagnostic Laboratory at the 
University of Nebraska-Lincoln for further 
processing. Briefly, the tissues were embedded in 
paraffin, cut into 8 µm thick sections, and subjected to 
routine H&E staining. The levels of liver injury 
markers in serum, including AST and ALT, were 
analyzed using a Vitros-250 Chemistry Analyzer 
(Johnson & Johnson, New Brunswick, NJ, USA). 
Tissue lysate preparation and immunoblot 
analysis 
Tissues were minced in lysis buffer (150 mM 
NaCl, 50 mM Tris-HCl, pH7.5, 0.5% NP-40) 
supplemented with protease inhibitor, homogenized 
using a mini-homogenizer, and gently rotated for 30 
min at 4 °C. The obtained tissue lysates were 
centrifuged at 18,000 ×g at 4 °C for 20 min, and the 
supernatant was collected and measured for protein 
concentration. Tissue lysates that contained equal 
amounts of proteins were loaded on the NuPAGE 
Bis-Tris protein gel (Invitrogen) for immunoblot 
analysis [19]. Primary antibodies used were 
anti-NLRP3 mouse antibody (Adipogen, 
AG20B0014C100, 1:1000); anti-ASC rabbit antibody 
(Adipogen, AG25B0006C100, 1:1000); anti-Casp1 
(p10) mouse antibody (Adipogen, AG20B0044C100, 
1:1000); anti-tubulin rabbit polyantibody (Santa Cruz, 
Dallas, TX, USA, SC-5286, 1:200); anti-Nek7 rabbit 
antibody (Abcam, Cambridge, MA, USA, ab133514, 
1:10000); and anti-IL-1β goat antibody (R&D systems, 
Minneapolis, MN, USA, AF401NA, 1:2000). 
Quantitative PCR (qPCR) 
mRNAs were extracted using RNA-bee (Tel- 
Test, Friendswood, TX, USA) per the manufacturer’s 
instructions. 1 µg of total RNA was used for reverse 
transcription using a high-capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, 
CA, USA), followed by qPCR analysis using a CFX 
Connect Real-time system (Bio-Rad, Hercules, CA, 
USA). The genes of interest were normalized to the 
Hprt gene. 
Cytokine measurement and LDH release 
Cytokine analysis and LDH release were 
performed as described [19]. The release of LDH in 
medium was assessed using a CytoTox 96 
Nonradioactive Cytotoxicity Assay kit (Promega, 
Madison, WI, USA). Cytokine level was measured 





using ELISA kits, including IL-1β (eBioscience, San 
Diego, CA, USA, 88701388), IL-18 (MBL, Woburn, 
MA, USA, D042-3), TNFα (BioLegend, San Diego, CA, 
USA, 430901), and IL-6 (BioLegend, 431301). 
SVF preparation 
Upon sacrifice, eWAT was soaked in Hank’s 
balanced salt solution (HBSS, Sigma) on ice. After 
being washed in cold HBSS two times, eWAT from 2 
mice in the same group was combined and minced in 
HBSS containing 1 mg mL-1 type I collagenase 
(Sigma), followed by gently shaking at 37 °C for 30 
min. Every 15 min, the tissue samples were further 
mixed using a plastic pipette. After enzymatic 
digestion, the samples went through a cell strainer to 
remove any residue tissues. Cells were centrifuged at 
300 ×g for 10 min to separate SVF pellets from floating 
adipocytes. 
Flow cytometry analysis 
SVF cells or BMDMs were blocked with 
TrueStain fcX (BioLegend) for 15 min on ice in PBS 
containing 0.5% FBS, 2 mM EDTA. SVF cells were 
incubated with F4/80-APC antibody (BioLegend) or 
rat isotype-APC control antibody (BioLegend) for 30 
min on ice. BMDMs were incubated with both 
F4/80-APC antibody (BioLegend) and CD11-b-PE 
antibody (BioLegend) for 30 min on ice. Both rat 
isotype-APC and rat isotype-PE control antibodies 
(BioLegend) were used in BMDMs as controls. The 
cells were washed and subjected to flow cytometry 
analysis using a DxP10 FACSort flow cytometer (BD 
Biosciences, San Jose, CA, USA). The data were 
analyzed with FlowJo (BD Biosciences). 
Statistics 
The results of cell culture experiments were 
analyzed using Excel software. A two-tailed t test was 
employed to compare differences between two 
conditions. Each cell culture experiment was repeated 
3 or 4 times. R version 3.6.0 (R Core Team, The R 
Foundation for Statistical Computing, Vienna, 
Austria) [77] was used to analyze the results of animal 
experiments. The normality of the data was evaluated 
using a Shapiro-Wilks test. Because a low p-value 
from the Shapiro-Wilks test suggested that the data 
were not normally distributed, they were evaluated 
using a nonparametric Mann-Whitney test. 
Otherwise, the data were assumed to be normally 
distributed and analyzed using a two-tailed t test. For 
all statistical analyses, p < 0.05 was indicated by * and 
considered significant. p < 0.01 was indicated by **. 
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